Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab +/- Ipilimumab + TACE in Intermediate-stage HCC
NCT04340193Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2020
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 19
01
Overview
A Phase 3 trial of nivolumab, ipilimumab in hepatocellular carcinoma (HCC), sponsored by Bristol Myers Squibb. Started Sep 2020; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04340193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04340193.